33
Zhang Y#, Zhao J, Han J, Fan Y, Xiong Z, Zou X, Li B, Liu X, Li Z, Lu B*, Cao B*. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa. Microbiol Spectr. 2022 Apr 27;10(2):e0274021. doi: 10.1128/spectrum.02740-21.
34
Huang L#, Gu X, Zhang H, Cao B*. A glimpse into long COVID and symptoms - Authors' reply. Lancet Respir Med. 2022 Jun 10;S2213-2600(22)00212-0. doi: 10.1016/S2213-2600(22)00212-0.
35
Chang K#, Wang H#, Zhao J, Yang X, Wu B, Sun W, Huang M, Cheng Z, Chen H, Song Y, Chen P, Chen X, Gan X, Ma W, Xing L, Wang Y, Gu X, Zou X, Cao B*.Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii. Front Med (Lausanne). 2022 Jun 10;9:772372. doi: 10.3389/fmed.2022.772372.
36
Zhang X#, Shang L#, Fan G, Gu X, Xu J, Wang Y, Huang L, Cao B*. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. Front Med (Lausanne).2022 Jan 27;8:800492. doi: 10.3389/fmed.2021.800492.
37
Huang Z#, Li H, Liu S, Jia J, Zheng Y, Cao B*. Identification of Neutrophil-Related Factor LCN2 for Predicting Severity of Patients With Influenza A Virus and SARS-CoV-2 Infection. Front Microbiol. 2022 Apr 12;13:854172. doi: 10.3389/fmicb.2022.854172.
38
Yu J#, Li H, Jia J, Huang Z, Liu S, Zheng Y, Mu S, Deng X, Zou X, Wang Y, Shang X, Cui D, Huang L, Feng X, Liu W.J, Cao B*. Pandemic influenza A (H1N1) virus causes abortive infection of primary human T cells. Emerg Microbes Infect. 2022 Dec;11(1):1191-1204. doi: 10.1080/22221751.2022.2056523.
39
Huang L#, Li X#, Gu X#, Zhang H#, Ren L#, Guo L#, Liu M#, Wang Y#, Cui D, Wang Y, Zhang X, Shang L, Zhong J, Wang X, Wang J*, Cao B*. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 May 11;S2213-2600(22)00126-6. doi: 10.1016/S2213-2600(22)00126-6.
41
Zou X#, Suo L#, Wang Y#, Cao H#, Mu S, Wu C, Yan L, Qi X, Lu J, Lu B, Fan Y, Li H, Huang L, Ren L*, Liu B*, Cao B*. Concurrent pigeon paramyxovirus-1 and Acinetobacter baumannii infection in a fatal case of pneumonia. Emerg Microbes Infect. 2022 Dec;11(1):968-977. doi: 10.1080/22221751.2022.2054366.
42
Guo L#, Wang G#, Wang Y#, Zhang Q#, Ren L#, Gu X#, Huang T, Zhong J, Wang Y, Wang X, Huang L, Xu L, Wang C, Chen L, Xiao X, Peng Y, Julian C Knight, Dong T, Cao B*, Wang J*.SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022 Mar 23. doi: 10.1016/S2666-5247(22)00036-2.
43
Zhang X#, Peter Horby, Cao B*.COVID-19 can be called a treatable disease only after we have antivirals. Science Bulletin. Available online 19 February 2022.
44
Chang K#, Wang H, Zhao J, Yang X, Wu B, Sun W, Huang M, Cheng Z, Chen H, Song Y, Chen P, Chen X, Gan X, Ma W, Xing L, Wang Y*, Cao B*. Risk factors for polymyxin B-associated acute kidney injury. Int J Infect Dis. 2022 Jan 30;S1201-9712(22)00061-3. doi: 10.1016/j.ijid.2022.01.055. Online ahead of print.
45
Zou X#, Mu S#, Wang Y#, Guo L#, Ren L, Deng X, Li H, Zhao J, Zhang Y, Li H, Lu B, Huang C, Cao B*.Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients. Virologica Sinica. Available online 17 January 2022.DOI: https: //doi.org/10.1016/j.virs.2022.01.008
46
Gu X#, Huang L, Cui D, Wang Y, Wang Y, Xu J, Shang L, Fan G, Cao B*. Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study. EBioMedicine. 2022; 76: 103817. Published online.
47
张安汝#, 王启, 周朝娥, 张建港, 王晓娟, 赵建康, 鲁炳怀, 杨春霞, 谷丽, 马立艳,苏建荣, 曹彬, 王辉*. 碳青霉烯类耐药肠杆菌目细菌院内感染危险因素和临床预后分析. 中华医学杂志. 2021,101(21): 1572-1582.
